ProQR Therapeutics reported a net loss of 7.4 million euros, or 0.23 euros per share, in the second quarter of 2018 compared with a net loss of 11.3 million euros, or 0.47 euros per share, in the previous year’s second quarter, according to a press release.
Research and development costs for the quarter totaled 6 million euros compared with 7.6 million euros in 2017’s second quarter, while general and administrative costs were 2.6 million euros compared with 2.9 million euros.
The company had 33 million euros in cash and cash (Read more...)
Uncategorized